Alfentanil and Paranasal sinus hypersecretion - a phase IV clinical study of FDA data

Summary:

Paranasal sinus hypersecretion is reported only by a few people who take Alfentanil.

The phase IV clinical study analyzes which people take Alfentanil and have Paranasal sinus hypersecretion. It is created by eHealthMe based on reports of 1,266 people who have side effects while taking Alfentanil from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 04, 2022

1,266 people reported to have side effects when taking Alfentanil.
Among them, 1 person (0.08%) has Paranasal sinus hypersecretion.


What is Alfentanil?

Alfentanil has active ingredients of alfentanil hydrochloride. eHealthMe is studying from 1,270 Alfentanil users for its effectiveness, alternative drugs and more.

What is Paranasal sinus hypersecretion?

Paranasal sinus hypersecretion is found to be associated with 704 drugs and 386 conditions by eHealthMe.

Number of Alfentanil and Paranasal sinus hypersecretion reports submitted per year:

Could Alfentanil cause Paranasal sinus hypersecretion?

Gender of people who have Paranasal sinus hypersecretion when taking Alfentanil *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Paranasal sinus hypersecretion when taking Alfentanil *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 100 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common drugs people take besides Alfentanil *:

  1. Xigris: 1 person, 100.00%
  2. Propofol: 1 person, 100.00%

Common side effects people have besides Paranasal sinus hypersecretion *:

  1. Subarachnoid Haemorrhage (blood leaks into the space between two membranes that surround the brain): 1 person, 100.00%
  2. Papilloedema (optic disc swelling): 1 person, 100.00%
  3. Pancreatic Necrosis (death of pancreas tissue in pancreas): 1 person, 100.00%
  4. Multi-Organ Failure (multisystem organ failure): 1 person, 100.00%
  5. Local Swelling (swelling at the site of some application of substance or injury): 1 person, 100.00%
  6. Injury: 1 person, 100.00%
  7. Hyperglycemia (high blood sugar): 1 person, 100.00%
  8. Cerebral Haemorrhage (bleeding within the brain): 1 person, 100.00%
  9. Brain Oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain): 1 person, 100.00%
  10. Brain Death: 1 person, 100.00%

Common conditions people have *:

  1. Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Alfentanil and have Paranasal sinus hypersecretion?

Check whether Paranasal sinus hypersecretion is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Paranasal sinus hypersecretion and when was it recovered:

Expand to all the drugs that have ingredients of alfentanil hydrochloride:

Alternative drugs to, pros and cons of Alfentanil:

Common Alfentanil side effects:

Browse all side effects of Alfentanil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Paranasal sinus hypersecretion treatments and more:

COVID vaccines that are related to Paranasal sinus hypersecretion:

Common drugs associated with Paranasal sinus hypersecretion:

All the drugs that are associated with Paranasal sinus hypersecretion:

Common conditions associated with Paranasal sinus hypersecretion:

All the conditions that are associated with Paranasal sinus hypersecretion:

How the study uses the data?

The study uses data from the FDA. It is based on alfentanil hydrochloride (the active ingredients of Alfentanil) and Alfentanil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: